Home>Topics>>The Contrarian View: Let's Not Put All Our Money On Lorcaserin Just Yet
The Contrarian View: Let's Not Put All Our Money On Lorcaserin Just Yet
Healthcare Sector and Stocks Analysis from Seeking Alpha
Fri, 7 Dec 2012
By Ed Liston : On the face of it, the FDA's approval of Arena Pharmaceuticals' ( ARNA ) Lorcaserin as an effective obesity drug is a buy signal. More so because this is the first obesity drug that the FDA has approved in 13 years, excluding Qsymia from Vivus ( VVUS ). Apparently there are plenty of ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.